Role of Lung Function, Airway Inflammation and Bronchial Hyper Reactivity for Exercise Capacity in Well-trained Individuals

What this Trial Is About

This research investigates how lung function, airway inflammation, and bronchial hyperreactivity affect exercise capacity in well-trained individuals aged 18 to 39. The study evaluates exercise performance after prolonged inhalation of beta2-agonists combined with corticosteroids, specifically vilanterol with fluticasone furoate and indacaterol with mometasone furoate. The goal is to understand how these treatments influence exercise capacity and lung function in healthy, physically active people who have high or very high maximal oxygen consumption. Participants are randomly assigned to inhale one of three treatments daily: vilanterol plus fluticasone furoate, indacaterol plus mometasone furoate, or a placebo. Each treatment is inhaled once per day over an average period of eight weeks. This quadruple-masked study compares the effects of the two active drug combinations to placebo to assess their impact on exercise performance. During the study, participants will perform exercise time trials to measure their exercise capacity, which is the primary outcome. Lung function tests are also conducted regularly as a secondary outcome. The study involves monitoring participants' physical activity and lung health while tracking inhalation adherence. The total participation duration is about eight weeks, during which researchers assess changes in exercise ability and respiratory function under the different treatment conditions.

Role of Lung Function for Exercise Capacity in Well-trained Individuals